FDA 483 - LCC Ltd. - March 22, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
LCC Ltd., an OTC drug manufacturer in Eumseong, Korea, received 11 observations during an FDA inspection, highlighting severe deficiencies across its quality control unit, laboratory controls, and manufacturing processes. The firm failed to maintain raw data, conduct adequate stability studies, and provide requested records, indicating a fundamental lack of cGMP understanding among personnel. These issues collectively demonstrate a significant breakdown in ensuring drug product quality and safety.
ID · 44c93a34-0fa7-4938-a170-66660546a92e